Technical Use of BFH772 (VEGFR2 inhibitor) in Angiogenesis Research

What This Product Solves

BFH772 is a potent, selective small-molecule VEGFR2 inhibitor designed for rigorous interrogation of the VEGFR2 signaling pathway within angiogenesis research. By inhibiting VEGFR2 with an IC50 of 3 nM, BFH772 enables precise modulation of VEGF-A, VEGF-B, VEGF-C, VEGF-D, and PlGF-driven pathways, offering a controlled approach to dissecting the role of vascular endothelial growth factor signaling in tumor angiogenesis and other vascular processes. Its strong selectivity—demonstrated by over 500-fold reduced potency against related receptors FLK-1, FLT-1, and FLT-4, and approximately 40-fold lower efficacy against B-RAF, RET, and TIE-2—makes it a targeted tool for studies where off-target kinase inhibition is undesirable. Researchers seeking to model or inhibit VEGFR2-driven angiogenesis in vitro or in vivo, especially in tumor models, will find BFH772 a suitable compound for protocols demanding high specificity. However, its poor water solubility and selectivity constraints make it inappropriate for workflows requiring aqueous formulations or broad-spectrum kinase inhibition. See BFH772 (VEGFR2 inhibitor) for full product details.

Protocol Parameters

• Assay: VEGFR2 kinase inhibition
  Value: IC50 = 3 nM
  Applicability: Use in in vitro kinase assays or cell-based models targeting VEGFR2-dependent signaling.
  Rationale: Enables reliable, high-affinity blockade of VEGFR2-mediated pathways for mechanistic or pharmacology studies.
  Source: Product dossier
• Solubility: ≥53.4 mg/mL in DMSO; ≥15.33 mg/mL in ethanol; insoluble in water
  Applicability: Suitable for DMSO- or ethanol-based stock solutions; not compatible with protocols requiring water-soluble reagents.
  Rationale: Maximizes achievable working concentrations while maintaining compound integrity. Requires solvent compatibility in downstream assays.
  Source: Product dossier
• Storage: -20°C recommended for solid powder; avoid long-term storage of solutions
  Applicability: Stable for long-term storage as a solid; freshly prepare stock solutions prior to use.
  Rationale: Prevents compound degradation and maintains batch-to-batch consistency.
  Source: Product dossier
• Specificity: ~500-fold lower potency versus FLK-1, FLT-1, FLT-4 receptors
  Applicability: Appropriate for experiments requiring minimal off-target kinase effects.
  Rationale: Reduces confounding effects from non-VEGFR2 kinases in angiogenesis assays.
  Source: Product dossier
• Recommended working concentration: 1–100 nM (workflow recommendation)
  Applicability: Typical range for cell-based or enzymatic inhibition studies; titrate as needed to define optimal inhibition window.
  Rationale: Concentrations should be empirically validated for each system to balance efficacy and cytotoxicity.
  Source: Workflow recommendation

Workflow Setup and QC Checklist

• Stock Preparation: Dissolve BFH772 in DMSO or ethanol to prepare concentrated stocks. Avoid water-based solvents due to insolubility. Filter sterilize if sterility is required. Confirm complete dissolution visually; undissolved material indicates insufficient solvent or improper mixing.
• Aliquoting and Storage: Prepare single-use aliquots to minimize freeze-thaw cycles. Store aliquots at -20°C in tightly sealed, light-protected vials. Discard any unused solution after use; do not refreeze.
• Assay Buffer Compatibility: Ensure final DMSO or ethanol concentration in working solution does not exceed cytotoxic levels for your assay system (typically ≤0.1–0.5%). Validate buffer compatibility in pilot tests.
• Purity and Identity Verification: Confirm batch purity (≥96%) with supplied certificate of analysis. Cross-check lot number and CAS (890128-81-1) for traceability.
• Positive/Negative Controls: Incorporate vehicle controls (DMSO/ethanol) and, if possible, known VEGFR2 inhibitors or inactive analogs for benchmarking specificity.
• Documentation: Maintain batch records, storage logs, and safety data sheets as provided by APExBIO for reproducibility and compliance.

For additional operational details, the article "BFH772 (VEGFR2 inhibitor): Technical Guidance for Angiogenesis Research" reviews solubility and selectivity boundaries in depth. Further, "BFH772 (VEGFR2 inhibitor): Practical Use and Protocol Guidelines" offers procedural insights for tumor model applications.

Common Failure Modes and Fixes

• Incomplete Dissolution: If visible particulates persist after vortexing or sonication in DMSO/ethanol, increase solvent volume or gently warm (avoid exceeding 37°C). Never attempt water-based dissolution.
• Loss of Potency: Decreased activity may result from repeated freeze-thaw cycles or prolonged storage of stock solutions. Always prepare fresh aliquots and discard any solution stored beyond recommended timelines.
• Precipitation in Assay Media: If precipitation occurs upon dilution, ensure gradual and vigorous mixing when adding concentrated stock to assay media. Pre-warm media if appropriate, and confirm that final solvent concentration is within tolerated range for your assay.
• Variable Results Across Batches: Audit batch number and purity for each experiment. Use aliquots from the same batch for comparative studies to minimize inter-batch variability.
• Off-target Effects: If unexpected phenotypes are observed, include additional controls and consider secondary kinase profiling to rule out non-VEGFR2 activity, especially at higher concentrations.

Scope and Limitations

• Scope: BFH772 is optimized as a selective VEGFR2 kinase inhibitor for angiogenesis research, especially in tumor models or systems requiring precise pathway modulation. Its high affinity and selectivity enable targeted investigation of VEGFR2-driven biological processes.
• Limitations: Not suitable for workflows demanding water-soluble compounds, as BFH772 is insoluble in water. Not intended for broad-spectrum kinase inhibition studies due to its narrow selectivity profile. Efficacy and toxicity should be empirically validated for each model; data on non-tumor or non-angiogenic contexts remain limited to product dossier descriptions. BFH772 is supplied for research use only and is not for clinical or diagnostic applications.

Conclusion

BFH772 provides a robust, selective tool for researchers investigating the VEGFR2 signaling axis in angiogenesis, with particular utility in tumor angiogenesis models. Its defined selectivity profile, documented solubility requirements, and stringent storage protocols support reproducible, high-confidence results when workflow best practices are followed. For full technical details, refer to the BFH772 (VEGFR2 inhibitor) product page. Careful adherence to recommended protocols and explicit recognition of its limitations will optimize experimental outcomes and data reliability.